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ttp://dx.doi.org/10.1016/j.ajpath.2013.11.030Apoptosis signal-regulating kinase 1 (ASK1), also known as mitogen-activated protein kinase kinase kinase
(MAP3K), is ubiquitously expressed and situated in an important upstream position of many signal trans-
duction pathways. ASK1 plays a pivotal role in stressor-induced cell survival and inﬂammatory reactions. To
ascertain the regulatory functions of ASK1 in bile duct ligation (BDL)einduced liver injury, we examined the
net effects of ASK1 depletion on hepatic necroinﬂammation and/or ﬁbrosis. We subjected C57BL/6 wild-type
(WT) or ASK1-deﬁcient (ASK1/) mice to sham or BDL surgery for 14 days. In day 3 BDL animals, ASK1/
mice had signiﬁcantly fewer bile infarcts along with more reduced interlobular or portal inﬂammatory inﬁl-
trate of various immune cells, including neutrophils, compared with WT mice in which ASK1 expression was
markedly activated. Morphologically apoptotic hepatocytes or cholangiocytes were negligible in both the
sham and BDL animals. In contrast, ASK1/ mice had signiﬁcantly less proliferating activity of not only
hepatocytes but also large cholangiocytes than WT mice. Day 14 BDL ASK1/ mice manifested potential
antiﬁbrogenic aspects of ASK1 deﬁciency, characterized by signiﬁcantly fewer activated peribiliary ﬁbrogenic
cells and peribiliary ﬁbrosis. These observations indicate that ASK1-mediated hepatic necroinﬂammation and
proliferation, but not apoptosis, are closely linked to liver ﬁbrosis and ﬁbrogenesis. A speciﬁc ASK1 pathway
blocker or inhibitor might offer a therapeutic strategy against human cholestatic diseases. (Am J Pathol
2014, 184: 644e661; http://dx.doi.org/10.1016/j.ajpath.2013.11.030)This work was supported in part by Grants-in-Aid for Scientiﬁc Research
(19590413, 20590416, and 24790394) from the Ministry of Education, Cul-
ture, Sports, Science and Technology, Tokyo, Japan (S.Y., A.T., and Y.S.).
H.N. and S.Y. contributed equally to this work.
Disclosures: None declared.It was previously proposed that hepatocytes undergoing
apoptosis might provide a critical hit to drive progression
from chronic inﬂammation to cirrhosis, especially in
cholestatic injury, such as primary biliary cirrhosis, primary
sclerosing cholangitis, biliary atresia, or chronic cholelithi-
asis, with reference to a single laboratory.1e4 In striking
contrast, several other groups5e9 have recently suggested
that there is no evidence of hepatocellular apoptosis using
morphologic criteria, but not terminal deoxynucleotidyl
transferase end-labeling (TUNEL) staining, in or around
necrotic foci (ie, bile infarcts) after bile duct ligation (BDL),
which is used to induce cholestasis in rodents.1e3,5e9 Theystigative Pathology.
.also concluded that BDL-induced oncotic necrosis but not
apoptosis of hepatocytes is closely correlated with the
severity of the inﬂammatory response, including high che-
mokine and/or cytokine expression.6,8,9 Meanwhile,
although cholangiocytes are a minor component of liver
cells, comprising merely 3% to 4% of the rodent liver, cells
lining the large bile ducts (large cholangiocytes) are the
Role of ASK1 in BDLmain target in animal models of cholestasis and intractable
human cholestatic diseases.10,11 Previous studies revealed
that rodent cholangiocytes are mitotically dormant under
basal conditions, whereas large but not small cholangiocytes
undergo signiﬁcant proliferation, leading to subsequent liver
ﬁbrosis after BDL injury, even though morphologic or
functional heterogeneity is noted in large versus small
cholangiocytes.12e14 Nevertheless, the regulation of biliary
injury and proliferation during cholestasis is multifactorial
and complex, and the various roles of large cholangiocytes
in the initiation and progression of cholestatic liver diseases
are still debatable.12,14 Hence, key factors and signaling
pathways that control the responses to injury in not only
hepatocytes but also cholangiocytes need to be identiﬁed.
Apoptosis signal-regulating kinase 1 (ASK1) is a mitogen-
activated protein kinase kinase kinase (MAP3K) family mem-
ber that is activated through distinct mechanisms in response to
various cytotoxic stressors, including oxidative stress mediated
by hydrogen peroxide, endoplasmic reticulum (ER) stress, and
immune system mediators, such as tumor necrosis factor
(TNF)-a, IL-1b, or Fas ligands.15,16 ASK1 is situated in an
important upstream position for many signal transduction
pathways, such as the c-Jun N-terminal kinase (JNK) and p38
MAP kinase (MAPK), which subsequently induce inﬂamma-
tion and intrinsic apoptotic signaling through mitochondria-
dependent caspase activation.15e17 Previous reports using
ASK1/ mice or ASK1 overexpressing transgenic mice
conﬁrmed that ASK1 plays a pivotal role in the regulation of
cardiomyocyte apoptosis in ischemia-reperfusion injury
models.18,19 Moreover, we recently found that activation of
ASK1 signaling enhances hyperlipidemia-induced necrotic
lipid core formation by inducing macrophage apoptosis and
acceleratesmechanical injuryeinducedvascular remodelingvia
increased neovascularization and proinﬂammatory reaction and
by stimulating apoptosis of smooth muscle cells and/or endo-
thelial cells.17,20 ASK1 plays a signiﬁcant role in the regulation
of vascular cell apoptosis and inﬂammatory signaling in vivo
and is correlated with plaque vulnerability in atherosclerosis.20
Other studies report that ASK1 expression plays a critical role
in vivo in the regulation of apoptosis in type 2 pneumocytes in
lung injury, with both antiapoptotic and anti-inﬂammatory
properties.21 However, few studies have investigated the rela-
tionship between ASK1 signaling pathway and cholestasis-
induced injury, even though ASK1 is ubiquitously expressed.
In the current study, we examined the roles of ASK1 in
BDL-induced cholestatic liver injury using mice genetically
deﬁcient for ASK1 (ASK1/). Furthermore, we aimed to
determine the net effects and key factors of ASK1 in liver
necroinﬂammation or subsequent ﬁbrosis.
Materials and Methods
Animals and BDL Model
Experiments were performed using 6- to 8-week-old, male,
C57BL/6 wild-type (WT) and ASK1/ mice,17,20 weighingThe American Journal of Pathology - ajp.amjpathol.org18 to 22 g, maintained in a temperature and light-controlled
facility with free access to standard rodent chow diet and
water. ASK1/ mice were developed on a C57BL/6 back-
ground.17,20 To produce a ligation-induced cholestatic liver
injury (BDL) model, the peritoneal cavity was opened after a
midline upper-abdominal incision, and the common bile duct
was double-ligated with sterile surgical 7-0 silk sutures
(Alfresa Pharma Corp., Tokyo, Japan) and cut between the
ligatures in two groups of mice at 6 to 8 weeks of age under
anesthesia [intraperitoneal injection of ketamine (100 mg/kg)
(Daiichi Sankyo Co., Tokyo, Japan) and medetamidine (2
mg/kg) (Meiji Yakuhin Co., Tokyo, Japan)], as previously
described.20 Sham-operated mice, as controls, underwent
laparotomy with exposure but no ligation of the common bile
duct. The fascia and skin of the midline abdominal incision
were closed with sterile surgical 6-0 silk sutures (Alfresa
Pharma Corp.). After a deﬁned period of BDL or sham
operation at 3 or 14 days, animals were euthanized by
exsanguination under reanesthetization with an i.p. injection
of ketamine-medetamidine, as follows: the peritoneal cavity
was reopened, and blood samples were taken from the infe-
rior vena cava, followed by immediate cannulation of the
suprahepatic vena cava. In all animals, after blood was
ﬂushed out of the liver via the suprahepatic vena cava cath-
eter, livers were excised and cut into small pieces and used
for various experiments as described below. The 24-hour
urine of day 3 BDL mice was collected using mouse meta-
bolic cages (Sugiyama-Gen Co., Ltd., Tokyo, Japan).
The Ethics Committee of Animal Care and Experimen-
tation, University of Occupational and Environmental
Health (Japan), approved the protocols. They were per-
formed according to the Institutional Guidelines for Animal
Experiments and the Law (no. 105) and Notiﬁcation (no. 6)
of the Japanese government. The investigation conformed to
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health.
Histopathology
Liver specimens were stained with H&E, Masson’s tri-
chrome, or picrosirius red stain, or immunohistochemistry
(IHC) preparations in sequential sections, after ﬁxation in
10% neutral buffered formalin for 24 hours.17,20,22e25 An-
alyses were performed in BDL-induced cholestatic livers in
all experiments, whereas the sham-operated livers served as
controls.
Livers embedded in parafﬁn for histologic examination
were cut systematically in sequential sections of 4-mm
thickness using a sliding microtome (Leica SM2010R;
Leica Microsystems, Wetzler, Germany). For histologic
analyses of the liver, images of H&E and special stained
sections or IHC sections were captured and quantiﬁed using
NanoZoomer Digital Pathology Virtual Slide Viewer soft-
ware version 2.0 (Hamamatsu Photonics Corp., Hamamatsu,
Japan). H&E-stained liver sections were used to measure the
areas of bile infarcts (hepatic necrosis) and calculate the645
Table 1 Primers Used for Real-Time PCR and RT-PCR
Gene Primer
Real-time PCR primers
ASK1
Forward 50-ACGACCACCTCAGGGTCATTC-30
Reverse 50-TGGTCAGTTTCACAAAGTGTTTATATATCAG-30
Probe 50-AGACTGAAGACACCAGCGTGGTACCTCAAGT-30
Caspase-3
Forward 50-AAGCCGAAACTCTTCATCATTCAG-30
Reverse 50-AGCCTCCACCGGTATCTTCTG-30
Probe 50-TGGACTGTGGCATTGAGACAGACAGTGG-30
Bak
Forward 50-CTGGAACCCAACAGCATCTTG-30
Reverse 50-TGGTGAAGAGTTCGTAGGCATTC-30
Probe 50-CGGAGATGATATTAACCGGCGCTACGAC-30
Bax
Forward 50-ATGGGCTGGACACTGGACTTC-30
Reverse 50-GAGGACTCCAGCCACAAAGATG-30
Probe 50-TGGCTGGGAAGGCCTCCTCTCCTACT-30
IL-1b
Forward 50-TGCACTACAGGCTCCGAGATG-30
Reverse 50-GTACAAAGCTCATGGAGAATATCACTTG-30
Probe 50-TGTCGGACCCATATGAGCTGAAAGCTCTC-30
IL-1R1
Forward 50-AGTTAAAAGCCAGTTTTATCGCTATCC-30
Reverse 50-CCCCCGATGAGGTAATTCTTG-30
Probe 50-AAATATTTTTGAGTCGGCGCATGTGCAGTTAAT-30
IL-6
Forward 50-TTACACATGTTCTCTGGGAAATCG-30
Reverse 50-TTGGTAGCATCCATCATTTCTTTG-30
Probe 50-TGAGAAAAGAGTTGTGCAATGGCAATTCTGAT-30
NF-kB
Forward 50-CTGACCCCTGTCCTCTCACATC-30
Reverse 50-CCGGTTTACTCGGCAGATCTT-30
Probe 50-TGATAACCGGGCCCCCAACACTG-30
TNF-a
Forward 50-CCCAGACCCTCACACTCAGATC-30
Reverse 50-TGCTCCTCCACTTGGTGGTT-30
Probe 50-ATTCGAGTGACAAGCCTGTAGCCCACG-30
TNFR2
Forward 50-TGGTCTGATTGTTGGAGTGACATC-30
Reverse 50-GGATTTCTCATCAGGCACATGAG-30
Probe 50-TGCATCATCCTGGTGCAGAGGAAAAAGA-30
TLR4
Forward 50-CAGAACTTCAGTGGCTGGATTTATC-30
Reverse 50-TAGGGTTTCCTGTCAGTATCAAGTTTG-30
Probe 50-ACAAGGCATGGCATGGCTTACACCAC-30
IFN-g
Forward 50-CATTCATGAGTATTGCCAAGTTTGAG-30
Reverse 50-GCTTCCTGAGGCTGGATTCC-30
Probe 50-CCACAGGTCCAGCGCCAAGCATT-30
iNOS
Forward 50-GCAGTGGAGAGATTTTGCATGAC-30
Reverse 50-ATGGACCCCAAGCAAGACTTG-30
Probe 50-CACCACAAGGCCACATCGGATTTCAC-30
TGFb-1 Mm00441724-m1 (Applied Biosystems Japan, Ltd.,
Tokyo, Japan).
PRDX1
Forward 50-TGTGGATTCTCACTTCTGTCATCTG-30
(table continues)
Noguchi et alpercentage of necrotic area divided by total area. In addition,
apoptotic cells were identiﬁed in 10 randomly selected ﬁelds
of interlobular and portal tracts per these H&E sections
(original magniﬁcation, 400), using morphologic criteria
(cell shrinkage, chromatin condensation and margination,
and apoptotic bodies).5e9 Liver ﬁbrosis was quantiﬁed by
Masson’s trichrome and picrosirius red staining (Picrosirius
Red Stain Kit; Polysciences, Inc., Warrington, PA) in 10
randomly selected ﬁelds of portal and periportal tracts per
section (original magniﬁcation, 400). In periportal tracts,
ﬁbers stained red with yellow birefringence under polarized
light were deﬁned as expressing collagen type I.25 The
proportions of collagen content were calculated for indi-
vidual images in cholestatic BDL livers, excluding large bile
ducts (>15-mm diameter) and vessels.
Analyses of Hepatic Cholestasis (BDL)eInduced Injury
Serum levels of total bilirubin and hepatic injuryerelated
enzymes, including aspartate aminotransferase (AST),
alanine aminotransferase (ALT), alkaline phosphatase, and
total bile acids, were measured using commercial assay kits
(Wako Pure Chemical Co., Osaka, Japan). To examine the
hepatic bile acids, snap frozen liver tissue (30 mg) was
homogenized and extracted with chloroform-methanol (2/1
v/v) solution. The organic phase was dried and resolubilized
in 2-propanol. Then the hepatic contents of bile acids were
determined using commercial assay kits (Wako Pure
Chemical Co.). Urinary bilirubin concentrations were
normalized with creatinine levels.
IHC and Double-Immunoﬂuorescence Staining
One representative sequential section per mouse was pre-
pared for IHC staining and was captured and evaluated by a
NanoZoomer Digital Pathology Virtual Slide Viewer
(Hamamatsu Photonics Corp.) to avoid potential
bias.17,20,23e25 Liver sections were stained with a goat
polyclonal anti-mouse cytokeratin 19 (CK19) antibody
(1:50; Santa Cruz Biotechnology, Santa Cruz, CA) to
highlight the lining of small and large bile ducts (small and
large cholangiocytes, respectively). For various analyses,
the bile ducts were separated according to size (small,<15-
mm diameter; large, >15-mm diameter).12,14 We excluded
tangentially sectioned bile ducts, where one cross-sectional
diameter was three times larger than another diameter, from
all analyses.12,14 The hyperplastic and proliferating bile
ductules were identiﬁed in the interface areas of portal tracts
per section. In addition, intrahepatic bile duct mass (IBDM)
was measured as followed: area occupied by CK19þ bile
ducts/total area  100.26
To evaluate the severity of BDL-induced cholestasis on day
3, we determined the intensity of inﬂammation using a poly-
clonal rabbit anti-human CD3 antibody (1:1; Dako Cytoma-
tion Co., Tokyo, Japan), a rat anti-mouse Mac-2 monoclonal
antibody (1:500; Cedarlane Laboratories Ltd., Burlington,646 ajp.amjpathol.org - The American Journal of Pathology
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Gene Primer
Reverse 50-GTGCGCTTGGGATCTGATATTAAG-30
Probe 50-CACACCCAAGAAACAAGGAGGATTGGGA-30
PRDX2
Forward 50-CCCAGAATTACGGCGTGTTG-30
Reverse 50-CCCTTGGCATCGATGATAAAGA-30
Probe 50-AATGATGAGGGCATTGCTTACAGGG-30
PRDX3
Forward 50-GGTGCTTTTCTTCTACCCTTTGG-30
Reverse 50-CACAGTTTACATCATGAAATTCATTGG-30
Probe 50-TTGTGTGTCCTACAGAAATTGTTGC-30
PRDX4
Forward 50-TGGACGAGACACTGCGTTTG-30
Reverse 50-CTGGATCTGGGATTATTGTTTCACTAC-30
Probe 50-ACACTGACAAGCATGGAGAAGTCTGCCC-30
PRDX5
Forward 50-GGAAGGCGACAGACTTATTATTGG-30
Reverse 50-CTCCACGTTCAGTGCCTTCAC-30
Probe 50-CGTCGGCTGAAAAGGTTCTCCATGGT-30
PRDX6
Forward 50-GCCAAGAGGAATGTTAAGTTGATTG-30
Reverse 50-GTTTCACCATTGTAAGCATTGATGTC-30
Probe 50-CAATAGACAGTGTTGAGGATCATCATCTTGCCTGG-30
CYP7A1
Forward 50-CGTGATCCTCTGGGCATCTC-30
Reverse 50-CTCTTGGCCAGCACTCTGTAATG-30
Probe 50-CAATGAAAGCAGCCTCTGAAGAAGTGAATGG-30
Catalase
Forward 50-CCCTCCTCGTTCAGGATGTG-30
Reverse 50-TGATATCGTGGGTGACCTCAAAG-30
Probe 50-ACAGAGAGCGGATTCCTGAGAGAGTGGTACA-30
SOD1
Forward 50-TGCAGGGAACCATCCACTTC-30
Reverse 50-CATGCTGGCCTTCAGTTAATCC-30
Probe 50-AAGCGGTGAACCAGTTGTGTTGTCAGGA-30
SOD2
Forward 50-GCCTGCACTGAAGTTCAATGG-30
Reverse 50-ACCCAAAGTCACGCTTGATAGC-30
Probe 50-CTGGACAAACCTGAGCCCTAAGGGTGG-30
FXR
Forward 50-CTGGAATATATGAACTCAGGCGTATG-30
Reverse 50-CCACAAACAACACACAGCTCATC-30
Probe 50-TAGCAGAGATGCCTGTAACAAAGAAGCCCC-30
SHP
Forward 50-AAGGAGTATGCGTACCTGAAGG-30
Reverse 50-CTCCAAGACTTCACACAGTGC-30
Probe 50-CTCTTCAACCCAGATGTGCCAGGC-30
VCAM-1
Forward 50-CTCATTCCCTGAAGATCCAGTAATTAA-30
Reverse 50-TCAAAGGGATACACATTAGGGACTGT-30
Probe 50-TGAGTGGGCCACTTGTGCATGGG-30
ICAM-1
Forward 50-CAAACAGGAGATGAATGGTACATACG-30
Reverse 50-ACCAGAATGATTATAGTCCAGTTATTTTGAG-30
Probe 50-CCATGGGAATGTCACCAGGAATGTGTACC-30
LFA-1
Forward 50-GGCCCCAGACTTTTGCTACTG-30
Reverse 50-GCAAGACCTGGTACCCAAAATG-30
(table continues)
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Gene Primer
Probe 50-CTACAACCTGGACACACGGCCTACGC-30
VLA-4
Forward 50-CATCGTATATGAAATGAAAGGTAAAAAGC-30
Reverse 50-GATCTGAGAAGCCATCTGCATTG-30
Probe 50-GATCTGAGAAGCCATCTGCATTG-30
PDGF-BB
Forward 50-AAGATCGAGATTGTGCGGAAGA-30
Reverse 50-AGCTGCCACTGTCTCACACTTG-30
Probe 50-AAGGCCACGGTGACGCTGGAAG-30
PDGFRB
Forward 50-GCTCACGGTCTGAGCCATTC-30
Reverse 50-GACTCATAATCTTCAGCTCGGACATT-30
Probe 50-ATGCTGAAATCGACAGCCAGAAGTAGCGA-30
18s rRNA TaqMan Ribosomal RNA Control Reagents VIC Probe
(Applied Biosystems, Foster City, CA; Cat. No.
4308329)
RT-PCR primers
ASK1
Forward 50-GCCGTGCTGGACCGTTTTTAC-30
Reverse 50-GTGAGGCGTGATGTAAATAGGAAGC-30
Neomycin
Forward 50-CTAAAGCGCATGCTCCAGACTGCCTTG-30
Reverse 50-GTGAGGCGTGATGTAAATAGGAAGC-30
GAPDH
Forward 50-AATGCATCCTGCACCACCAACTGC-30
Reverse 50-GGAGGCCATGTAGGCCATGAGGTCC-30
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1:500; Birmingham, AL).6,8,23e25,27 We counted the number
of positive T lymphocytes, macrophages (Kupffer cells), and
neutrophils in 10 randomly selected ﬁelds of portal and
interlobular areas per section, respectively (original
magniﬁcation,400).25 In addition, the number of neutrophils
present in the sinusoids and extravasated into the parenchymal
tissue were counted in 10 randomly selected high-power ﬁelds
of interlobular and portal areas of similar size per section,
respectively (original magniﬁcation, 400). The sum of si-
nusoidal and extravasated neutrophils was expressed as the
total neutrophil sequestration in the liver.28 Also, protein ad-
ducts of chlorotyrosine, as a useful marker of neutrophil-
induced cytotoxicity, were detected by IHC using a rabbit
antichlorotyrosine polyclonal antibody (1:50; Hycult Biotech,
Uden, Netherlands).28
To assess the activation of peribiliary ﬁbrogenic cells (ie,
myoﬁbroblasts) in BDL-injured portal tracts, we used a
HistoMouse Plus Kit (Invitrogen Corp., Camarillo, CA) to
block endogenous IgG and then stained tissues in mirror
images of sequential sections with monoclonal mouse anti-
human a-smooth muscle actin (a-SMA) (1:1000; Dako)
and anti-human desmin (1:150; Dako) antibodies, as pre-
viously described.29 The number of activated peribiliary
ﬁbrogenic cells (ie, myoﬁbroblasts) was counted in 10
randomly selected ﬁelds of periportal or portal tracts per
section, respectively (original magniﬁcation: 400).25,28647
Noguchi et alFor double-immunoﬂuorescence, injured livers at day 14
BDL were labeled with mouse monoclonal a-SMA
(1:1000; Dako) and goat polyclonal CK19 antibodies
(1:50; Santa Cruz Biotechnology) and visualized with goat
anti-mouse IgG antibodies conjugated with Alexa Fluor
Dyes (red stained) and donkey anti-goat IgG antibodies
conjugated with Alexa Fluor Dyes (green stained) (Invi-
trogen, Carlsbad, CA), respectively.20,24 We applied the
HistoMouse Plus Kit (Invitrogen) to block endogenous
mouse IgG.17,20,23e25
To analyze the proliferative activity of bile ducts, Ki67
(MIB-1; 1:2000; Epitomics, Cambridge, UK) rabbit mono-
clonal antibody was applied. For double-immunoﬂuorescence
of proliferating cholangiocytes, injured livers of day 3 BDL
mice were labeled with rabbit monoclonal Ki67 (1:2000;
Epitomics) and goat polyclonal CK19 antibodies (1:50; Santa
Cruz Biotechnology) and visualized with goat anti-rabbit IgG
antibodies conjugated with Alexa ﬂuor Dyes (green stained)
and donkey anti-goat IgG antibodies conjugated with Alexa
ﬂuor Dyes (red stained) (Invitrogen), respectively.20,24 More
than 100 large or small cholangiocytes were counted in 10
randomly selected ﬁelds of portal or periportal tracts per sec-
tion and viewed by confocal laser scanning microscopy
(LSM5 Pascal Exciter; Carl Zeiss, Oberkochen, Germany)
(original magniﬁcation, 400).
To evaluate ASK1 expression in BDL-injured or sham-
operated livers, we used mouse monoclonal antibody to
phosphorylated ASK1 (p-ASK1; 1:200; Wako Pure Chem-
ical Co.).17,20
For IHC or immunoﬂuorescence studies, we examined one
section from each of 5 or 10 mice per experimental group. All
histologic and IHC slides were evaluated by two independent
certiﬁed pathologists (Sohsuke Yamada and Shohei Shimajiri)
who were masked to the physical outcome or other biological
and pathological data for each sample. In case of disagreement,
a consensus score was determined by a third board-certiﬁed
pathologist (Yasuyuki Sasaguri). Agreement between ob-
servers was excellent (>0.9) for all sections investigated as
measured by interclass correlation coefﬁcient.TUNEL and 50-Bromo-20-Deoxyuridine (BrdU) Staining
TUNEL assays were performed using an In Situ Cell Death
Detection Kit (POD; Roche Applied Science, Mannheim,
Germany).17,20,23e25 In addition, BDL-injured livers on day 3
were labeled with antiﬂuorescein antibodies (brown stained)
(TUNEL POD; Roche Applied Science) or ﬂuorescein-
conjugated TUNEL reaction mixture (green stained) (Roche
Applied Science) and goat polyclonal anti-CK19 antibody
(1:50; Santa Cruz Biotechnology) and, for the latter, visualized
with donkey anti-goat IgG antibodies conjugated with Alexa
Fluor Dyes (red stained) (Invitrogen) by confocal laser scan-
ning microscopy (LSM5 Pascal Exciter) (original magniﬁca-
tion, 400).20,24 For quantitative analysis, we counted
TUNELþ hepatocytes and cholangiocytes (brown stained) in64810 randomly selected ﬁelds around the bile infarcts per section
(original magniﬁcation, 400).25
To label proliferating large to small cholangiocytes in
injured livers 3 days after BDL, BrdU (50 mg/kg body
weight; Sigma, St. Louis, MO) was subcutaneously injected
2 hours before sacriﬁce. BrdU-incorporated cells were
detected by IHC using a monoclonal mouse anti-BrdU
antibody (Roche Applied Science, Lewes, UK).17,20,24
High-Performance Liquid Chromatography Analysis of
Lipoprotein
Three days after BDL, the mice were fasted for 7 hours, and
blood was collected from the inferior vena cava into a
microtube that contained 5 mL of 0.5 mol/L EDTA. Samples
were centrifuged for 12 minutes at 5500  g at 4C, and the
resulting serum was stored at 80C until assayed. Lipo-
proteins were analyzed by high-performance liquid chro-
matography using molecular sieve columns (Skylight
Biotech Inc., Akita, Japan), as previously described.17,24,25,30
Measurement of Serum TBARS Levels
As a quantitative marker of oxidative stress closely associ-
ated with the development of cholestasis on day 3 after BDL
surgery, we measured serum thiobarbituric acid reactive
substance (TBARS) levels using a TBARS Assay Kit
(Cayman Chemical Company, Ann Arbor, MI).24,25 Results
are expressed as nanomoles of malondialdehyde (MDA) per
milligram of low-density lipoprotein (LDL) protein.
RT-PCR and Real-Time RT-PCR
Total RNAs were extracted with Trizol reagents (Invi-
trogen) from livers of mice sacriﬁced on day 3 or 14 after
BDL injury, after careful removal of blood cells, using the
sham-operated livers as controls. All procedures were per-
formed as described previously.17,20,2225,30 RNase-free
conditions were used to prevent mRNA degradation. First-
strand cDNA was synthesized with Superscript II RT
(Invitrogen) using random primers, according to the man-
ufacturer’s instructions. Quantitative real-time RT-PCR was
performed using the TaqMan ﬂuorogenic probe method
with a LightCycler 480 System II PCR machine (Roche
Diagnostics K.K., Tokyo, Japan). Sequences of speciﬁc
primers for RT-PCR are summarized in Table 1. Cycling
conditions were as follows: 50C for 2 minutes and 95C for
10 minutes followed by 45 cycles of 95C for 15 seconds
and 60C for 1 minute. The CT values were measured
corresponding to the cycle number at which the ﬂuorescent
emission, monitored in real time, reached a threshold of 10
SDs above the mean baseline from cycles 1 to 15. Serial
1:10 dilutions of plasmid DNA that contained each target
cDNA were analyzed and served as standard curves from
which the rate of change of CT values was determined. Copy
numbers of target cDNA were estimated by standard curves.ajp.amjpathol.org - The American Journal of Pathology
Role of ASK1 in BDLAll reactions for samples were performed in triplicate.
Mean data were obtained from values of each reaction. To
determine mRNA levels of various genes, an mRNA
expression index was used where mRNA expression levels
are standardized by 18s rRNA (Applied Biosystems, Foster
City, CA). The mRNA expression index in arbitrary units
(AU) was calculated as follows: mRNA expression indexZ
(copy numbers of target gene mRNA/copy numbers of 18s
rRNA)  1 AU.
Microarray Studies and Data Analysis
DNA microarray analysis was performed using 3D-Gene
software (Toray Industries, Kamakura, Kanagawa, Japan),
as previously described.31 High-quality RNA samples (1 mg
each) prepared from injured livers of WT and ASK1/ mice
sacriﬁced on day 3 after BDL were ampliﬁed and labeled
with cyanine 3 and cyanine 5 CTP (Amersham Biosciences
Corp., Piscataway, NJ) to produce labeled cRNA using
Agilent low-RNA-input ﬂuorescent linear ampliﬁcation kits
following the manufacturer’s protocol. After ampliﬁcation
and labeling, the dye-incorporation ratio was determined
using a Nanodrop spectrophotometer, and ratios were within
10 to 20 pM per microgram of cRNA. For hybridization,
750 ng of cyanine 3e and 750 ng of cyanine 5elabeled
cRNA was fragmented and hybridized to an Agilent Tech-
nologies Human 1A (V2) Gene Expression Microarray
using the Agilent Gene Expression hybridization kit as
described in the Two-Color Microarray-Based Gene
Expression Analysis Version 4.0 manual. After hybridiza-
tion, microarrays were washed and scanned with the Agilent
dual-laser DNA microarray scanner. Scans were converted
to data ﬁles with Agilent Feature Extraction software
(version 8.5). Data were deposited in Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession no.
GSE23969) and analyzed with Microsoft Access version
2010 and Spotﬁre version 7.0 (Spotﬁre, Somerville, MA).
Arrays were scanned by Agilent dual-laser DNA micro-
array scanner using SureScan technology, extracted by
feature Extraction software version 7.1, and analyzed by
Rosetta Resolver software version 3.2, build (3.2.2.0.33)
(Rosetta Biosoftware, Kirkland, WA). Three replicate
samples were used for each experiment. Genes were se-
lected as signiﬁcant using criteria of greater than twofold
(up- or down-regulated) changes.
Preparation of Liver Hepatocytes and Analysis of ASK1
Expression
Liver hepatocytes were isolated from 8-week-old male
ASK1/ andWTmice fed a normal chow diet, as previously
described.25 All mice were anesthetized by i.p. injection of
ketamine (Daiichi Sankyo Co.) and medetamidine (Meiji
Yakuhin Co.). The abdominal cavity was opened, and the
mesenteric and bilateral renal arteries were ligated. A ligature
was placed around the portal vein at a site distal to theThe American Journal of Pathology - ajp.amjpathol.orgbifurcation and another around the inferior vena cava at a site
proximal to the mesenteric artery. A tapered polyethylene
cannula connected to a perfusion apparatus was inserted
into the portal vein and was ligated in place. An 18-G
needle was also inserted into the vena cava and ligated in
place. Then liver perfusion medium (GIBCO17701-038;
Gibco, Grand Island, NY) and collagenase type II solution
medium (Gibco) with an oxygen and carbon dioxide
mixture (95:5) at 37C were injected into the cannula (4.5
mL/min). The collected cells were washed with Dulbecco’s
modiﬁed Eagle’s medium; cultured in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine
serum, 1% penicillin-streptomycin (Gibco), and 2 mmol/L
glutamine (Gibco) at a density of 2 to 3  105 cells/cm2;
and placed onto six-well glass slides in an incubator for>3
days. Adherent cells (hepatocytes) were maintained in the
medium.
For p-ASK1 staining, hepatocytes were ﬁxed in 95%
acetone for 30 seconds at room temperature and per-
meabilized in 0.1% Triton X-100 for 2 minutes at 4C.
Cells were then stained with a mouse monoclonal anti-
body to p-ASK1 (1:100; Wako Pure Chemical Co.) for 1
hour, washed with PBS, and reacted with Alexa Fluor
Dyes (red stained)econjugated goat anti-mouse IgG anti-
bodies (Invitrogen). Isolated hepatocytes were observed
and images immediately captured with a Nikon ECLIPSE
E600 inverted ﬂuorescence microscope (Nikon, Tokyo,
Japan). We applied the HistoMouse PlusKit (Invitrogen) to
block endogenous mouse IgG.
Western Blot Analysis
Proteins (40 mg) isolated from BDL-injured livers of WT
and ASK1/ mice were separated by SDS-PAGE and
transferred to Immun-Blot polyvinylidene diﬂuoride mem-
branes (Bio-Rad Laboratories, K.K., Tokyo, Japan) using a
semidry blotter.17,20,22e25,30 The blotted membranes were
treated with 5% (w/v) skimmed milk in 10 mmol/L Tris,
150 mmol/L NaCl, and 0.2% (v/v) Tween-20 and incubated
for 1 hour at room temperature with primary antibody. The
following antibodies and dilutions were used: mouse
monoclonal antibodies to phosphorylated JNK (p-JNK),
JNK, phosphorylated p38 (p-p38), p38, proliferating cell
nuclear antigen (PCNA) (1:200; Santa Cruz Biotechnology),
or p-ASK1 (1:1000; Wako Pure Chemical Industries); goat
polyclonal antibody to caspase-3 precursor (procaspase-3;
32 kDa) and caspase-3 subunit (active fragment; 11 kDa)
(1:200; Santa Cruz Biotechnology)6; rabbit monoclonal
antibody to ASK1 (1:2000; Abcam, Cambridge, UK); rabbit
polyclonal antibodies to Bax (1:50; Santa Cruz Biotech-
nology); inducible nitric oxide synthase (iNOS: 1:200; BD
Biosciences, San Jose, CA); or transforming growth factor
b1 (activated TGF-b1: 25 kDa; 1:200; Santa Cruz
Biotechnology) and 1:5000 dilution of antieb-actin (Santa
Cruz Biotechnology). The membranes were then incubated
for 45 minutes at room temperature with a peroxidase-649
Figure 1 Analysis of ASK1 mRNA and protein expression in mice. A: RT-PCR
of ASK1 expression in livers of ASK1/ and WT mice subjected to BDL surgery
(n Z 10 mice per group) and of controls (sham operated) (n Z 5 mice per
group). B: IHC of p-ASK1 at day 3 after BDL surgery (nZ 10 mice per group).
p-ASK1 is present in many hepatocytes and large but not small (inset) chol-
angiocytes throughout the livers ofWTmice,butnot inASK1/mice, and sham-
operated animals. Immunoﬂuorescence staining of p-ASK1 (red stained) in
cultured hepatocytes harvested from WT and ASK1/ mice (inset). C: Western
blot analysis of p-ASK1, ASK1, p-JNK, and p-p38 in day 3 BDL livers of ASK1/
and WT mice (nZ 10 mice per group) and control sham-operated mouse livers
(nZ 5 mice per group). Scale barZ 25 mm. Values were normalized for GAPDH
expression (RT-PCR) (A) and for b-actin expression (Western blotting) (C).
Noguchi et al
650conjugated secondary antibody and visualized using an ECL
kit (GE Healthcare Bio-Science, Buckinghamshire, En-
gland, UK). Bands on Western blots were analyzed densi-
tometrically using Scion Image software (version 4.0.2;
Scion Corp., Frederick, MD).
ELISA for TNF-a and IL-1b
Levels of serum TNF-a and IL-1b in the BDL-injury model
on day 3 were measured using an enzyme-linked immuno-
sorbent assay (ELISA) kit according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN).17,20,23e25
Electron Microscopy
At day 14 after BDL surgery, injured livers from ASK1/
and WT mice were ﬁxed with 2.5% glutaraldehyde, and
small specimens were cut (approximately 1  1 mm),
including large cholangiocytes, and were immersed in 2%
osmium tetroxide and dehydrated in ethanol. For trans-
mission electron microscopy, dehydrated tissue specimens
were embedded in epoxy resin. Silver-gold sections pro-
duced with a diamond knife were transferred to copper grids
and stained with uranyl acetate for viewing on a trans-
mission electron microscopy (JEM-1200EX; JEOL Ltd.,
Tokyo, Japan).
Statistical Analysis
Results are expressed as means  SEM. Signiﬁcant differ-
ences were analyzed using Student’s t-test, Welch’s t-test, or
one-way analysis of variance where appropriate. In all cases
when the analysis of variance method was used for
nonparametric data, Tukey’s multiple comparison post hoc
test was used.17,20,24,25 P < 0.05 was considered statistically
signiﬁcant.
Results
Expression of ASK1, p-ASK1, p-JNK, and p-p38 Is
Absent or Decreased in Sham-Operated and/or BDL-
Injured Livers of ASK1/ Mice
Liver mRNA and protein expression levels of ASK1 and/or
p-ASK1 were detected by RT-PCR and Western blotting,
respectively. PCR clearly revealed no expression of ASK1 in
the livers of ASK1/ mice with or without BDL on day 3
(Figure 1A). ASK1 was only detected in WT mice, and its
expression was signiﬁcantly greater in BDLWTmice than in
sham-operated WT mice (Figure 1A). In addition, immuno-
ﬂuorescence studies found that hepatocytes obtained from
WT mice, but not those from ASK1/ mice, expressed
intracellular p-ASK1 (Figure 1B, inset). However, biochem-
ical and morphologic (ratio of liver to body weight) studies
revealed no differences in livers of ASK1/ and WT mice
under basal conditions (data not shown).ajp.amjpathol.org - The American Journal of Pathology
Role of ASK1 in BDLIn mice subjected to day 3 BDL surgery, IHC (Figure 1B)
and Western blotting (Figure 1C) conﬁrmed that p-ASK1
and ASK1 protein was speciﬁcally expressed throughout the
livers of WT mice (Figure 1, B and C), especially in chol-
angiocytes lining large but not small (Figure 1B, inset) bile
ducts and hepatocytes around bile infarcts, but was not
present in ASK1/ mice and sham-operated animals
(Figure 1B). Moreover, Western blotting analysis revealed
that the expression of p-JNK and p-p38 in BDL-injured
livers in ASK1/ mice on day 3 was also signiﬁcantly
reduced compared with WT mice (Figure 1C).
Deletion of ASK1 Suppresses Acute Cholestatic Liver
Injury
The serum levels of ALT and AST were signiﬁcantly
increased in WT mice after 3 days of BDL compared with
ASK1/ mice (Figure 2A), indicative of more extensive
hepatocyte necrosis and cell death (apoptosis). Similarly,
total plasma and conjugated bilirubin (Figure 2B), plasma
bile acid concentration (Figure 2C), hepatic levels of bile
acids (Figure 2C), and cholesterol, especially very low-
density lipoprotein (VLDL) and low-density lipoprotein
(LDL) (data not shown), were signiﬁcantly elevated in WT
mice compared with ASK1/ mice on day 3 after BDL
surgery and control mice (P < 0.05 or P < 0.001,
P < 0.001, and P < 0.0001, respectively). These in vivoFigure 2 Effects of ASK1 deletion on plasma aminotransferases, bilirubin, bile
AST and ALT levels in day 3 BDL WT and ASK1/ mice (nZ 10 mice per group) a
Total and conjugated bilirubin levels in day 3 BDL WT and ASK1/ mice (nZ 10
Levels of plasma and hepatic bile acids in day 3 BDL WT and ASK1/ mice (n Z
bilirubin levels in day 3 BDL WT and ASK1/ mice (n Z 10 mice per group) and
*P < 0.05, **P < 0.001, and ***P < 0.0001.
The American Journal of Pathology - ajp.amjpathol.orgbile acid levels <300 mmol/L (Figure 2C) in the BDL
models are insufﬁcient to not only directly cause liver cells
death but also trigger inﬂammatory mediators formation, as
described in the recent review paper.32 Accumulation of
conjugated bilirubin contributed to increased plasma bili-
rubin levels in both groups of mice with BDL (Figure 2B).
The serum levels of alkaline phosphatase were markedly
higher in the day 3 posteBDL surgery mice groups
(2444  491 U/L for the WT mice versus 2529  322 U/L
for the ASK1/ mice) compared with sham-operated ani-
mals (165  10 U/L for the WT mice versus 135  21 U/L
for the ASK1/ mice); however, no signiﬁcant difference
was found between ASK1/ and WT mice at day 3 after
BDL surgery or controls, respectively (data not shown).
According to the serum cholesterol proﬁles by high-
performance liquid chromatography in mice at day 3 after
BDL surgery, no signiﬁcant difference was found in total
cholesterol, high-density lipoprotein, or triglyceride levels
between the two groups (data not shown). Both day 3
posteBDL surgery WT and ASK1/ mice developed hy-
percholesterolemia and hypotriglyceridemia, with signiﬁ-
cantly increased levels of total cholesterol, VLDL, and
LDL but decreased high-density lipoprotein cholesterol
and triglyceride levels compared with control animals (data
not shown). In addition, BDL resulted in increased urine
bilirubin levels in WT and ASK1/mice. A similar pattern
was observed without statistical signiﬁcant between theacid levels, and hepatic bile acid levels in the murine BDL model. A: Plasma
nd control (sham-operated) mice (nZ 5 mice per group) (P < 0.0001). B:
mice per group) and control mice (nZ 5 mice per group) (P < 0.0001). C:
10 mice per group) and control mice (n Z 5 mice per group). D: Urine
sham-operated animals (n Z 5 mice per group). Values are means  SEM.
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Figure 3 Histologic analysis of BDL-induced bile infarcts. A: Repre-
sentative H&E-stained liver sections of WT and ASK1/ mice 3 or 14 days
after BDL surgery (nZ 10 mice per group) are shown. Sham-operated livers
from both groups of mice served as controls (n Z 5 mice per group). B:
Quantitative analysis of day 3 and day 14 posteBDL surgery ASK1/ and
WT mice (conﬂuent necrotic foci of hepatocytes, indicated by yellow ar-
rows). Injured livers in WT mice at day 14 after BDL surgery displayed a
signiﬁcantly smaller amount of infarcted areas, indicative of a faster repair
process to acute cholestatic injury, compared with ASK1/ mice. Values
are means  SEM. **P < 0.001 and ***P < 0.0001. Scale barZ 200 mm.
C, central vein; P, portal vein.
Noguchi et altwo groups of mice at day 3 after BDL surgery (Figure 2D).
No statistical differences between genotypes were
observed in sham-operated animals for any of the above
parameters (Figure 2).
ASK1-Deﬁcient Hepatocytes Are More Resistant to
Acute Cholestatic Liver Injury but Delay Regeneration
of BDL-Injured Livers
Corresponding to the above AST, ALT, or bilirubin data, the
area of bile infarcts was signiﬁcantly more extensive in WT
mice than in ASK1/ mice at day 3 after BDL surgery
(8.51%  0.60% for WT mice versus 2.64%  0.58% for
ASK1/ mice; P < 0.0001) and control mice (P < 0.0001),
respectively (Figure 3, A and B). Although liver histologic
analysis in WT mice at day 14 after BDL surgery revealed652signiﬁcantly faster repair processes of acute cholestatic injury
and smaller infarcted areas compared with ASK1/ mice
(2.15%  0.40% for WT mice versus 3.87%  0.54% for
ASK1/ mice; P < 0.05) (Figure 3, A and B). No signiﬁcant
difference was found between areas of bile infarcts at day 3
and 14 after BDL surgery in ASK1/ mice, unlike in WT
mice (P < 0.0001; Figure 3B). In addition, no difference was
found in the ratios of liver to body weight at day 14 after
BDL surgery between the two groups of mice (data not
shown). However, signiﬁcantly decreased cholestatic com-
plications and mortality were observed in ASK1/ mice 21
days after BDL surgery compared with WT mice (overall
survival: 50.8%  5.6% for WT mice versus 77.8%  5.7%
for ASK1/ mice; P < 0.0001) (Supplemental Figure S1),
whereas all control animals were free of complications and
did not die during the study period.
Deletion of ASK1 Does Not Affect Apoptotic Activity of
Both Hepatocytes and Large Cholangiocytes after BDL
On the basis of morphologic analysis, such as cell
shrinkage, chromatin condensation and margination, and
formation of apoptotic bodies, the numbers of apoptotic
liver cells 3 days after BDL surgery (0.04%  0.01% in WT
mice versus 0.03%  0.01% in ASK1/ mice of all he-
patocytes; approximately 0.4 cells per 10 ﬁelds, respec-
tively) (0.01%  0.01% in WT mice versus 0.01%  0.01%
in ASK1/ mice of all large cholangiocytes) were negli-
gible (Supplemental Figure S2A) and not signiﬁcantly
increased compared with sham-operated controls
(0.02%  0.02% of all hepatocytes) (0.01%  0.01% of all
large cholangiocytes) in the H&E sections. Consistent with
these ﬁndings, no signiﬁcant differences were found in
caspase-3 activities and caspase-3 processing (Supplemental
Figure S2B) or Bax expression (data not shown) in Western
blotting analysis between the respective groups (WT versus
ASK1/ mice and BDL versus sham surgery).
In striking contrast, the number of TUNELþ interlobular
hepatocytes around bile infarcts was signiﬁcantly lower in
ASK1/ mice compared with WT mice (45.9  2.4 per 10
ﬁelds in WT mice versus 39.6 2.6 per 10 ﬁelds in ASK1/
mice; P < 0.05) (data not shown). However, staining pattern
was diffuse over the entire cell and did not remain conﬁned to
the nucleus as was seen in true apoptotic hepatocytes. Also,
these oncotic hepatocytes were swollen with total nuclear
fragmentation or cell lysis (ie, characteristics of necrosis).
Therefore, no morphologically apoptotic characteristics were
identiﬁed in most of the TUNELþ hepatocytes. Furthermore,
the number of TUNELþ large cholangiocytes was signiﬁ-
cantly lower in ASK1/ mice than in WT mice (7.6  0.5
per 10 ﬁelds in WT mice versus 5.8  0.4 per 10 ﬁelds in
ASK1/ mice; P < 0.05) (data not shown) but that of
TUNELþ small cholangiocytes was not (8.2  0.7 per
10 ﬁelds in WT mice versus 8.1  0.7 per 10 ﬁelds in
ASK1/ mice) (data not shown). Similarly, the morphologic
characteristics of apoptosis were not noted in the TUNELþajp.amjpathol.org - The American Journal of Pathology
Role of ASK1 in BDLcholangiocytes. In fact, double-immunoﬂuorescence staining
(data not shown) revealed that there were no apoptotic (green
stained) CK19þ large cholangiocytes (red stained). Livers of
sham-operated control mice revealed no injury and no
TUNELþ cells (data not shown).
Deletion of ASK1 Represses Inﬂammatory Reactions in
Interlobular and Portal Tracts after BDL Surgery
Gr-1 staining revealed signiﬁcantly more decreasing
numbers of accumulated neutrophils not only per injured
interlobular areas in sinusoids or extravasated into the
parenchymal tissue (total: 139.6  4.1 per 10 ﬁelds in WT
mice versus 105.8  4.1 per 10 ﬁelds in ASK1/ mice;
P < 0.0001) (extravasated: 91.7  2.6 per 10 ﬁelds in WT
mice versus 61.5  3.0 per 10 ﬁelds in ASK1/ mice;
P < 0.0001) (Figure 4A), but also per injured portal tracts
(69.8 3.6 per 10 ﬁelds inWTmice versus 61.5 2.9 per 10
ﬁelds in ASK1/ mice; P < 0.05) (Figure 4B) in ASK1/Figure 4 Analysis of inﬁltrating neutrophils and adhesion molecule expressio
accumulated neutrophils per injured interlobular areas in sinusoids or extravasate
surgery (nZ 10 mice per group). Approximately 66% of these neutrophils were extr
fewer (58%) of those were located in the parenchyma in ASK1/ livers. Positiv
interlobular areas around conﬂuent bile infarcts of day 3 post-BDL WT livers. Fewe
ASK1/mice (nZ 5 mice per group), and no neutrophils extravasated into the par
in ASK1/ and WT livers at day 3 after BDL surgery (nZ 10 mice per group). C: Real
1, in the injured livers of WT and ASK1/ mice (n Z 10 mice per group) at day
means  SEM and were normalized for 18s rRNA expression (real-time RT-PCR). *P
The American Journal of Pathology - ajp.amjpathol.orglivers than in WT livers at day 3 after BDL surgery.
Approximately 66% of these neutrophils were extravasated
into the injured interlobular areas of WT livers, whereas 58%
of those were located in the parenchyma in ASK1/ livers
(P < 0.05) (Figure 4A). Moreover, signiﬁcantly extensive
positive staining for chlorotyrosine protein adducts was
recognized, especially in these interlobular areas around
conﬂuent bile infracts of day 3 posteBDL surgeryWT livers,
indicating that the extravasated neutrophils were cytotoxi-
cally active.28 Only <5 neutrophils per 10 high-power ﬁelds
were noted in sham-operated controls of both WT and
ASK1/ mice, respectively (data not shown), and no neu-
trophils were observed extravasated into the parenchyma.
Furthermore, IHC for CD3 revealed that modestly injured
livers in ASK1/ mice contained signiﬁcantly fewer inﬁl-
trating T lymphocytes, especially around large bile ducts in the
portal tracts, compared with WT mice at day 3 after BDL
surgery (132.0  10.1 per 10 ﬁelds in WT mice versus
100.2  6.9 per 10 ﬁelds in ASK1/ mice; P < 0.05)n in BDL-induced cholestatic livers of mice. A: IHC reveals the number of
d into the parenchymal tissue of ASK1/ and WT mice at day 3 after BDL
avasated into the injured interlobular areas of WT livers, whereas signiﬁcantly
ity for chlorotyrosine protein adducts was recognized, especially in these
r than 5 neutrophils were noted in sham-operated controls of both WT and
enchyma. B: There were few accumulated neutrophils per injured portal tracts
-time RT-PCR of adhesion molecules, such as ICAM-1, VCAM-1, VLA-4, and LFA-
3 after BDL surgery and control mice (n Z 5 mice per group). Values are
< 0.05, **P < 0.001, and ***P < 0.0001. Scale barZ 25 mm.
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Figure 5 Analysis of inﬁltrating T lymphocytes
or Kupffer cells and proinﬂammatory reactions in
BDL-induced cholestatic livers of mice. A: IHC of
inﬁltrating CD3þ T lymphocytes and Mac-2þ mac-
rophages (Kupffer cells) around large bile ducts in
the portal tracts of day 3 BDL WT mice compared
with ASK1/ mice (n Z 10 mice per group) and
control mice (n Z 5 mice per group). B and C:
Real-time RT-PCR of TNF-a (B) and IL-1b (C)
expression in the injured livers of WT mice
compared with ASK1/ mice (n Z 10 mice per
group) and control mice (n Z 5 mice per group).
ELISA conﬁrmed gene expression. D: Real-time RT-
PCR and Western blotting of iNOS in day 3 post-
BDL livers of WT and ASK1/ mice (n Z 10
mice per group) and control mice (nZ 5 mice per
group). Values are means  SEM and were normal-
ized for 18s rRNA expression (real-time RT-PCR) or
b-actin expression (Western blotting), respectively.
*P< 0.05, **P< 0.001, and ***P< 0.0001. Scale
barZ 25 mm.
Noguchi et al(Figure 5A). Mac-2 staining also revealed signiﬁcantly fewer
macrophages, includingKupffer cells, per injuredportal tract in
ASK1/ livers than inWT livers (149.3 4.9 per 10 ﬁelds in
WT mice versus 137.5  3.1 per 10 ﬁelds in ASK1/ mice;
P < 0.05) (Figure 5A). Neither CD3-positive T lymphocytes
nor Mac-2epositive macrophages in interlobular areas around
bile infarcts had signiﬁcant differences in numbers between
the two groups of day 3 posteBDL surgery mice (CD3:
143.7 6.9 per 10ﬁelds inWTmice versus 136.0 7.6 per 10
ﬁelds in ASK1/ mice) (Mac-2: 162.9  2.8 per 10 ﬁelds in
WT mice versus 160.1  5.6 per 10 ﬁelds in ASK1/ mice).
Sham-operated animals had markedly fewer inﬂammatory
cells (Figure 5A).
Real-time RT-PCR revealed that the expression levels of
several adhesion molecules, such as intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), very late antigen-4 (VLA-4), and lymphocyte
function-associated antigen-1 (LFA-1) (Figure 4C), and
many proinﬂammatory signaling factors, such as TNF-a
(Figure 5B), TNF receptor (TNFR)2 (Supplemental FigureS3),
IL-1b (Figure 5C), IL-1 receptor (IL-1R) 1, IL-6, nuclear factor-
kappa B (NF-kB), interferon-g (IFN-g), Toll-like receptor 4
(TLR4) (Supplemental Figure S3), or iNOS (Figure 5D), were
signiﬁcantly down-regulated in the livers of day 3 posteBDL
surgery ASK1/ mice compared with WT and control mice
(P < 0.05, P < 0.001, and P < 0.0001, respectively). Corre-
sponding to these data, ELISA analysis found that serum
TNF-a (Figure 5B) and IL-1b (Figure 5C) levels were signiﬁ-
cantly lower in ASK1/ mice than in WT mice 3 days after
BDL ligation (TNF-a: 6.79  0.38 pg/mL in WT mice versus6545.61  0.56 pg/mL in ASK1/ mice, P < 0.05; IL-1b:
3.70  0.45 pg/mL in WT mice versus 1.44  1.30 pg/mL in
ASK1/ mice, P < 0.05). Moreover, the iNOS data were
conﬁrmed by Western blotting analysis (Figure 5D). No sta-
tistical differences between genotypes were observed in sham-
operated animals for any the above parameters.
Deletion of ASK1 Decreases Proliferating Activity of
Hepatocytes and Large Cholangiocytes after BDL
Surgery
It has been found that the proliferation of interlobular hepa-
tocytes and portal and periportal (interface) cholangiocytes
peaks during the ﬁrst 5 days after BDL surgery.32 At day 3
after BDL surgery, the numbers of hepatocytes around bile
infarcts (48.2 1.9 per 10 ﬁelds inWTmice versus 35.1 0.8
per 10 ﬁelds in ASK1/ mice; P < 0.001) (Figure 6A) and
Ki67þ large cholangiocytes (43.2  1.4 per 10 ﬁelds in WT
mice versus 35.1  0.8 per 10 ﬁelds I ASK1/ mice;
P< 0.001) (Figure 6B) were signiﬁcantly reduced inASK1/
mice compared with WT mice. In contrast, the number of
Ki67þ small cholangiocytes was relatively small and not
statistically different between the two groups of mice
(14.6  1.0 per 10 ﬁelds in WT mice versus 14.3  0.6 per
10 ﬁelds in ASK1/ mice). Double-immunoﬂuorescence
staining (Figure 6B) conﬁrmed that the proliferating cells
(green stained) were partly CK19þ large cholangiocytes (red
stained). Similarly, the proliferation activity of BrdUþ chol-
angiocytes in large bile ducts 3 days after BDL surgery was
signiﬁcantly different between the two groups of miceajp.amjpathol.org - The American Journal of Pathology
Figure 6 Analysis of proliferating liver cells in BDL-
induced cholestasis. A: The number of Ki67þ hepatocytes
(indicated by yellow arrowheads) was signiﬁcantly reduced
in ASK1/ compared with WT mice, measurements of Ki67þ
hepatocytes around bile infarcts, at day 3 after BDL surgery
(n Z 10 mice per group). B: Double-immunoﬂuorescence
staining revealed that proliferating cells in portal tracts
(Ki67þ, green stained) were large cholangiocytes (CK19þ, red
stained). The number of Ki67þ and CK19þ proliferating large
cholangiocytes (white arrowheads) was markedly decreased
in the portal tracts of day 3 post-BDL ASK1/ mice than in
WT mice (nZ 10 mice per group). BrdU incorporation at day
3 after BDL surgery conﬁrmed signiﬁcant differences in
proliferating large cholangiocytes between the two groups of
mice. Interestingly, a substantial number of Ki67þ or BrdUþ
oval to spindle myoﬁbroblast-like cells are noted in the portal
tracts of WT mice. Some BrdU-retaining spindle cells are
located within large bile ducts (red arrowheads). C: Western
blotting demonstrated that the hepatic expression of PCNA
was signiﬁcantly up-regulated in day 3 post-BDL WT and
ASK1/ mice (n Z 10 mice per group) and control sham-
operated mice (n Z 5 mice per group). Values are
means  SEM (A and B) and were normalized for b-actin
expression (Western blot analysis), respectively. **P < 0.001.
Scale bar Z 25 mm.
Role of ASK1 in BDL(Figure 6B). Interestingly, a substantial number of Ki67þ or
BrdUþ oval-to-spindle myoﬁbroblast-like cells were also
noted in portal tracts of WT mice at day 3 after BDL surgery
(Figure 6B). In addition, some of the BrdU-retaining spindle
cells were located within large bile ducts (Figure 6B).
Corresponding to the above histologic data, Western
blotting analysis revealed that the expression of PCNA in
modestly injured livers of ASK1/ mice at day 3 after BDL
surgery was signiﬁcantly decreased compared with WT
mice (Figure 6C). Sham-operated mice had no signiﬁcant
histologic or immunohistochemical differences between the
two groups for any of the above parameters.Deletion of ASK1 Does Not Affect the Antioxidant State
after BDL Surgery
Unexpectedly, serum TBARS levels were low in both
ASK1/ and WT mice at day 3 after BDL surgery and
without statistical difference (0.87  0.02 nmol MDA per
milligram of LDL protein in WT mice versus 0.86  0.04
nmolMDA per milligrams of LDL protein inASK1/mice).
Real-time RT-PCR revealed that the antioxidant family geneThe American Journal of Pathology - ajp.amjpathol.orgexpressions of peroxiredoxin (PRDX ) 1 to 6, catalase, or Cu,
Zn-superoxide dismutase (SOD) 1 to 2 were not signiﬁcantly
different between the two groups (data not shown).Deletion of ASK1 Represses Activation of Peribiliary
Fibrogenic Cells in or around Large Bile Ducts without
Signiﬁcant Proliferation after BDL Surgery
IBDM composed of CK19þ large-to-small bile ducts was
signiﬁcantly decreased in ASK1/ mice at day 14 after
BDL surgery compared with WT mice (10.3%  0.6% in
WT mice versus 8.8%  0.7% in ASK1/ mice; P < 0.05)
(Figure 7, A and B), indicating that deletion of ASK1 could
delay regenerative hyperplastic or proliferating responses of
bile ducts against BDL injury. Similarly, IHC of day 14
BDL ASK1/ mice livers revealed signiﬁcantly lower
speciﬁc and linear expression of a-SMA along the hyper-
plastic bile ductules and the hepatic sinusoids, in the
portal and periportal tracts, compared with WT mice
(5.9%  0.12% in WT mice versus 4.3%  0.1% in
ASK1/ mice; P < 0.001) (Figure 7, A and B). In mirror
images of these sequential sections, a-SMAþ but desmine655
Noguchi et alspindle to oval cells were easily detected in WT mice. These
were consistent with the overt activation of peribiliary
ﬁbrogenic cells (ie, myoﬁbroblasts), especially in WT mice,
as previously described.28 Similarly, real-time RT-PCR
revealed that the expression levels of platelet-derived growth
factor-BB (PDGF-BB) and PDGF receptor b (PDGFRB)
(Supplemental Figure S3) were signiﬁcantly down-regulated
in the livers of day 3 BDL ASK1/ mice compared with
WT and control mice (P < 0.05 and P < 0.0001, respec-
tively). Double-immunoﬂuorescence staining (Figure 7C)
revealed that a small number of hyperplastic CK19þ
cholangiocytes (green-stained) concomitantly had a
phenotype of a-SMAþmyoﬁbroblasts (red-stained) in WT
mice at day 14 after BDL surgery, which was rarely
observed in ASK1/ mice.
Ultrastructural Analysis of Portal Tracts in BDL-Injured
Livers
Electron microscopy was performed to determine the
phenotypes of ASK1-deﬁcient stellate cells or largeFigure 7 Measurements of IBDM and activated peribiliary ﬁbrogenic cells in
and desmin in portal and periportal tracts of day 14 BDL WT and ASK1/ mice (
group). C: Double immunoﬂuorescence staining of hyperplastic CK19þ cholang
(red stained) in WT and ASK1/ mice at day 14 after BDL surgery (yellow arr
bar Z 25 mm. P, portal vein.
656cholangiocytes in the portal and periportal tracts of day 14
BDL injured livers from ASK1/ mice. Peribiliary ﬁ-
brogenic cell phenotypes in the injured WT livers mainly
had synthetic myoﬁbroblast-like cells that contained
signiﬁcantly large amounts of cytoplasmic organelles,
such as rough ER or lysosomes, compared with ASK1/
mice (Supplemental Figure S4). ER and lysosome counts
per peribiliary ﬁbrogenic cell revealed statistically sig-
niﬁcant differences between the two groups of mice
(7.6  1.9 in WT mice versus 3.8  0.9 in ASK1/ mice;
P < 0.05).
However, large cholangiocytes in day 14 BDL livers
of ASK1/ mice had a signiﬁcantly higher density of
microvilli for each cell, which characterized a phenotype of
large or mature cholangiocytes33 compared with WT mice
(Supplemental Figure S4). Indeed, the morphologic features
of large cholangiocytes in day 14 BDL injured livers of WT
mice were not well preserved, displaying a signiﬁcant
decrease in density of microvilli per large cholangiocytes
(10.5  3.5 in WT mice versus 21.0  1.6 in ASK1/
mice; P < 0.05) (Supplemental Figure S4).the BDL-induced cholestatic livers of mice. A and B: IHC For CK19, a-SMA,
nZ 10 mice per group) and control sham-operated mice (nZ 5 mice per
iocytes (green-stained) and a-SMAþ activated peribiliary ﬁbrogenic cells
owheads). Values are means  SEM. *P < 0.05 and **P < 0.001. Scale
ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Analysis of peribiliary ﬁbrosis or ﬁbrogenesis in the BDL-
induced cholestatic livers of mice. A: Picrosirius red staining reveals
areas of peribiliary ﬁbrosis or ﬁbrogenesis in the cholestatic livers of
WT and ASK1/ mice at day 14 after BDL surgery (n Z 10 mice per
group) and sham-operated control mice (n Z 5 mice per group). Under
polarized light, the red-stained ﬁbers expressed collagen type I, as
shown by yellow birefringence. B: Real-time RT-PCR and Western
blotting of activated TGF-b1 in day 14 post-BDL livers of WT and
ASK1/ mice (n Z 10 mice per group) and control mice (n Z 5 mice
per group). Values are means  SEM and were normalized for 18s rRNA
expression (real-time RT-PCR) or b-actin expression (Western blotting),
respectively. *P < 0.05 and ***P < 0.0001. Scale bar Z 25 mm.
P, portal vein.
Role of ASK1 in BDLDeletion of ASK1 Suppresses Peribiliary Fibrosis or
Fibrogenesis after BDL
Corresponding to the above IBDM or a-SMA IHC ﬁndings
(Figure 7), picrosirius red staining revealed evidence of
signiﬁcantly greater peribiliary ﬁbrosis in WT mice at day
14 after BDL surgery than in ASK1/ mice (4.6%  0.2%
in WT mice versus 2.0%  0.1% in ASK1/ mice;The American Journal of Pathology - ajp.amjpathol.orgP < 0.0001) and control mice (P < 0.0001) (Figure 8A).
Similarly, Masson’s trichrome staining in injured livers 14
days after BDL revealed signiﬁcant differences between the
two groups of mice (data not shown). Furthermore, real-time
RT-PCR and Western blotting analyses revealed that the
expression level of activated TGF-b1 (Figure 8B) was
signiﬁcantly down-regulated in the livers of day 14 BDL
ASK1/ mice compared with WT and control mice
(P < 0.05).
No signiﬁcant differences between genotypes were
observed in sham-operated animals for any of the above
parameters. Both groups of control mice had markedly less
ﬁbrosis and ﬁbrogenesis compared with experimental groups
(Figures 7A and 8A).
Microarray and Real-Time RT-PCR Analyses Reveal
Variable Changes in Gene Expression Patterns,
including Regulatory Genes of Bile Acid Synthesis, in
BDL-Induced Cholestatic Models because of ASK1
Deﬁciency
To identify new mechanisms involved in the suppression of
liver necroinﬂammation and ﬁbrosis or ﬁbrogenesis
observed in ASK1/ mice, cDNA expression array ana-
lyses were performed comparing injured liver tissue samples
obtained from ASK1/ and ASK1þ/þ WT mice 3 days after
BDL surgery. A total of 86 genes revealed a twofold change
(58 up-regulated and 28 down-regulated genes) in ASK1/
mice. The top up-regulated and down-regulated genes are
listed in Supplementary Table S1. They include the up-
regulation of the cytochrome P450 families, such as
cholesterol 7a-hydroxylase (CYP7A1) or sterol 12a-hy-
droxylase (CYP8B1), components of bile acid meta-
bolism,34 and the down-regulation of IL-1 receptor type II
(IL-1R2), a proinﬂammatory mediator, as well as ASK1.
Real-time RT-PCR conﬁrmed that the expression level of
CYP7A1 (Supplemental Figure S3) was signiﬁcantly up-
regulated in the livers of day 3 BDL ASK1/ mice
compared with WT and control mice (P < 0.05 or
P < 0.0001, respectively). Conversely, the expression
levels of small heterodimer partner (SHP), but not farne-
soid X receptor (FXR) (Supplemental Figure S3), were
signiﬁcantly down-regulated in the modestly injured livers
of day 3 posteBDL surgery ASK1/ mice compared with
WT mice (P < 0.05).
Discussion
The present study reveals, for the ﬁrst time to our knowl-
edge, a critical protective role of depleted ASK1 in a BDL
injuryeinduced murine cholestasis model. Cholestasis-
induced necroinﬂammation and ﬁbrosis or ﬁbrogenesis
were signiﬁcantly reduced, and the survival rate was
increased in ASK1/ mice having no expression of ASK1
compared with WT mice that expressed higher levels of657
Figure 9 The critical roles of ASK1 in BDL-induced cholestasis. This
diagram depicts the diverse, key roles of ASK1 in the current BDL-induced
murine cholestatic model.
Noguchi et alp-ASK1. ASK1/ mice demonstrated potential anti-
inﬂammatory proﬁles, especially in the acute phase of day
3 after BDL surgery, including manifestations of reduced
bile infarcts, suppressed extensive inﬂammatory and
proinﬂammatory reactions, lowered local (intrahepatic) and
systemic (circulating) levels of bile acids, and decreased
proliferation, but not apoptosis, in hepatocytes and large
cholangiocytes. These effects also improved subsequent
peribiliary ﬁbrosis or ﬁbrogenesis in ASK1-deleted mice
with antiﬁbrogenic proﬁles in the subacute (to chronic)
phase of day 14 post-BDL injury. More recently, we found
that ASK1/ mice also had antiatherogenic (anti-inﬂam-
matory and/or antiﬁbrogenic) features, especially in me-
chanical injury (carotid artery ligation)einduced vascular
remodeling, manifesting as acute to subacute inﬂammatory
disease (atherosclerosis).20 In this context, ASK1 deﬁciency
would reveal signiﬁcant protective effects against acute to
subacute inﬂammatory injury. From other viewpoints,
because ASK1/ mice manifested as a delay of healing (ie,
delayed repair process) in day 14 BDL livers, deletion of
ASK1 might partly display a detrimental proﬁle in the sub-
acute to chronic phase after BDL. Figure 9 summarizes the
diverse roles of ASK1 in the murine BDL model. Further-
more, we proposed that BDL-induced oncotic necrosis and
proliferation, but not apoptosis, are closely correlated with
the severity of the inﬂammatory responses and that the
pathogenic roles of ASK1-mediated necroinﬂammation and
proliferation of not only hepatocytes but also large chol-
angiocytes are crucial in cholestasis-induced ﬁbrosis or
ﬁbrogenesis.
After establishing the BDLmodel, we detected the speciﬁc
expression of ASK1 and/or activated p-ASK1 in the injured
livers of WT mice by RT-PCR, IHC, and Western blotting
(Figure 1) but not in ASK1/ mice. Interestingly, IHC
(Figure 1B) revealed that there would be heterogeneity of
p-ASK1 expression proﬁles in large versus small chol-
angiocytes, almost parallel to the severity of BDL-induced
cholestatic injury, which might partly support the previous
ﬁndings regarding the functional heterogeneities in large to
small cholangiocytes.12e14 The MAP3K family is likely
stimulated by distinct mechanisms during the progression of
cholestatic liver injury in response to various immune system
mediators, such as TNF-a, IL-1b, or iNOS (Figure 6 and
Supplemental Figure S3), and/or unknown ER and oxidative
stressors. This subsequently increases the expression of
activated downstream p-p38 and p-JNK. Indeed, the
expression of these MAPK family members was signiﬁcantly
higher in WT livers than the modestly injured livers of
ASK1/ mice after BDL surgery (Figure 1C). However,
only <0.1% of hepatocytes or large cholangiocytes were
apoptotic even in both of the two groups at day 3 after BDL
surgery, respectively (Supplemental Figure S2A), using
morphologic criteria (ie, the gold standard to detect liver
cells undergoing apoptosis after BDL, according to much
of the recent data in the hepatology study).5e9 Moreover,
in particular, TUNELþ hepatocytes had no apoptotic658morphologic features because both of the nucleus and cytosol
were stained, which is known to be characteristic of early
necrosis.35 Thus, these ﬁndings indicate that apoptosis plays
little role in BDL-induced cholestasis and that ASK1/mice
could be a good model for determining the net effects of
blocked ASK1 signaling pathway in cholestatic necroin-
ﬂammation and ﬁbrosis.
Our data are in agreement with various previous obser-
vations from several other laboratories. Hepatic inﬂamma-
tion that involves the accumulation and recruitment of
neutrophils, Kupffer cells, or T lymphocytes (Figures 4 and
5), all of which are cellular components of the innate to
adapted immune system, plays a critical role in contributing
to a large fraction of oncotic necrosis and subsequent
ﬁbrosis or ﬁbrogenesis during murine BDL models.6,8,9,28
Moreover, it is accompanied by not only the stimulation
of various adhesion molecules and proinﬂammatory cas-
cades6,8,9,28 but also signiﬁcant up-regulation of TGF-b1.8,9
Interestingly, iNOS was markedly expressed in injured liver
cells of WT mice (Figure 5D) in response to hepatic acti-
vation through various inﬂammatory and proinﬂammatory
cytokines, including TNF-a or IL-1b (Figure 5, B and C and
Supplemental Figure S3), and stimulated p38 MAPK-
mediated signaling (Figure 1C), similar to mouse astro-
cytes or bovine chondrocytes, as previously described.36,37ajp.amjpathol.org - The American Journal of Pathology
Role of ASK1 in BDLFurthermore, corresponding to Yes-associated proteine
deﬁcient mice demonstrating suppressed proliferation of
large cholangiocytes in day 5 BDL livers with following
increased bile infarcts at day 15 after BDL surgery,38
ASK1/ mice had signiﬁcantly fewer proliferating hepa-
tocytes and large cholangiocytes and reduced PCNA
expression at day 3 after BDL surgery (Figure 5), together
with greater necrotic foci in day 14 BDL livers (Figure 3).
On the one hand, on the basis of a vast amount of results,
this is just a consequence of reduced early-phase liver injury
(ie, necroinﬂammation) in ASK1/ mice rather than ASK1
directly affecting proliferation. On the other hand, because
ASK1 is situated in an important upstream position for
many signal transduction pathways, ASK1 deﬁciency sup-
presses many signals required for not only inﬂammation but
also cell survival or proliferation.15,17,20 Therefore, the
ASK1 pathway might have a close relationship with PCNA-
induced proliferation signaling in liver cells, supported by
the reported data that inhibition of the JNK pathway induces
diminished proliferative responses to partial hepatectomy
together with decreased PCNA expression.39 Nevertheless,
further studies are needed to clarify those issues because
identifying promising key factors and pathways related to
the MAP3K family member, ASK1, would help control
hepatic responses against cholestasis-induced liver injury.
The present pathologic or molecular ﬁndings should be
remarkable for other reasons. First, double-immunoﬂuorescence
staining with CK19 and a-SMA indicated a small number
of hyperplastic cells (within IBDM) having phenotypes of both
cholangiocytes and peribiliaryﬁbrogenic cells, especially inWT
mice at day 14 after BDL surgery, butwhichwere absent or very
rare inASK1/mice (Figure7C).Thedouble-stained immature
and precursor-like cells should play a key role in the repair
process of injured cholangiocytes during cholestasis because
hyperplastic or proliferating cholangiocytes could originate
from pleiotropic hepatic stem or progenitor cells.40 Second, ul-
trastructural analysis conﬁrmed that hyperplastic large chol-
angiocytes inWTmice at day 14 after BDL surgery manifested
as a phenotype of immature cholangiocytes (ie, differentiation of
small into large cholangiocytes).12e14These cholangiocytes had
signiﬁcantly fewer microvilli, compared with ASK1/ mice,
and displayed overtly well-preserved morphologic features
(Supplemental Figure S4). Furthermore, electron microscopy
revealed that peribiliary ﬁbrogenic cells fromWTmice also had
a dedifferentiated (immature) synthetic myoﬁbroblast-like
phenotype, containing a signiﬁcantly larger number of cell
organelles (Supplemental Figure S4). This is similar to the
migrating intimal smooth muscle cells in injured arteries, as
previously described by us.20 The activated p38 MAPK
pathway plays a crucial role in myoﬁbroblastic dedifferen-
tiation of not only smooth muscle cells20,41 but also possibly
peribiliary ﬁbrogenic cells. These features are in line with
signiﬁcantly increased collagen production in day 14 BDL
livers from WT mice (Figure 8). Third, cDNA expression
array analyses revealed the signiﬁcant up-regulation of cyto-
chrome P450 families in ASK1/ mice livers at day 3 afterThe American Journal of Pathology - ajp.amjpathol.orgBDL surgery, including CYP7A1 or CYP8B1, which are key
regulated enzymes in bile acid synthesis (Supplemental Table
S1).42 Because signiﬁcantly lower levels of bile acids in the
ASK1/ livers (Figure 2C) possibly activate FXR less
and subsequently up-regulate SHP less (Supplemental
Figure S3), involving the inhibition of SHP-mediated
CYP7A1 repression,34 these data might be consistent with
the potential anticholestatic proﬁle, especially in the acute
phase of the BDL model.
In conclusion, on the basis of our collected data, we
postulate that ASK1 deﬁciency plays critical roles in
ameliorating cholestatic liver injury together with i)
decreased accumulation and recruitment of various inﬂam-
matory cells into interlobular and portal areas accompanied
by down-regulated expression of various adhesion mole-
cules and proinﬂammatory mediators, ii) reduced hepato-
cellular necrosis (bile infarcts), iii) suppressed proliferation
of hepatocytes and large cholangiocytes, iv) inactivation and
rare myoﬁbroblastic dedifferentiation in peribiliary ﬁbro-
genic cells, and v) repressed synthesis of collagen-rich
extracellular matrix by the above mechanisms, as summa-
rized in Figure 9. Hence, we can conclude that depletion of
ASK1 prevents the development of acute necroinﬂam-
mation and subsequent peribiliary ﬁbrosis or ﬁbrogenesis,
suppressing aberrant regenerative (proliferating) responses
and exerting beneﬁcial effects in BDL injuryeinduced
cholestasis. All these features indicate that a speciﬁc ASK1
pathway blocker could offer a therapeutic strategy against
the progression of human cholestatic liver disease.
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